F10 and cancer: The comparison of an oral Factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism (SELECT-D) study for rivaroxaban, the edoxaban for the treatment of cancer-associated venous thromboembolism (Hokusai VTE Cancer) study for edoxaban, and the apixaban for the treatment of venous thromboembolism associated with cancer (CARAVAGGIO) study for apixaban compared the efficacy of DOACs with that of LMWH, the first therapeutic choice for CAT treatment [11, 13, 14].